United States - English - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - chloroquine phosphate (unii: 6e17k3343p) (chloroquine - unii:886u3h6uff) - chloroquine phosphate 250 mg - chloroquine phosphate tablets are indicated for the suppressive treatment and for acute attacks of malaria due to p. vivax, p. malariae, p. ovale , and susceptible strains of p. falciparum. the drug is also indicated for the treatment of extraintestinal amebiasis. chloroquine phosphate tablets does not prevent relapses in patients with vivax or malariae malaria because it is not effective against exoerythrocytic forms of the parasite, nor will it prevent vivax or malariae infection when administered as a prophylactic. it is highly effective as a suppressive agent in patients with vivax or malariae malaria, in terminating acute attacks, and significantly lengthening the interval between treatment and relapse. in patients with falciparum malaria it abolishes the acute attack and effects complete cure of the infection, unless due to a resistant strain of p. falciparum . use of this drug is contraindicated in the presence of retinal or visual field changes either attributable to 4-aminoquinoline compounds

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - chloroquine phosphate (unii: 6e17k3343p) (chloroquine - unii:886u3h6uff) - chloroquine phosphate 500 mg - chloroquine phosphate tablets are indicated for the suppressive treatment and for acute attacks of malaria due to p. vivax, p.malariae, p. ovale , and susceptible strains of p. falciparum. the drug is also indicated for the treatment of extraintestinal amebiasis. chloroquine phosphate tablets does not prevent relapses in patients with vivax or malariae malaria because it is not effective against exoerythrocytic forms of the parasite, nor will it prevent vivax or malariae infection when administered as a prophylactic. it is highly effective as a suppressive agent in patients with vivax or malariae malaria, in terminating acute attacks, and significantly lengthening the interval between treatment and relapse. in patients with falciparum malaria it abolishes the acute attack and effects complete cure of the infection, unless due to a resistant strain of p. falciparum . use of this drug is contraindicated in the presence of retinal or visual field changes either attributable to 4-aminoquinoline compounds or to a

United States - English - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - chloroquine phosphate (unii: 6e17k3343p) (chloroquine - unii:886u3h6uff) - chloroquine phosphate 500 mg - chloroquine phosphate tablets are indicated for the suppressive treatment and for acute attacks of malaria due to p. vivax, p.malariae, p. ovale , and susceptible strains of p. falciparum. the drug is also indicated for the treatment of extraintestinal amebiasis. chloroquine phosphate tablets does not prevent relapses in patients with vivax or malariae malaria because it is not effective against exoerythrocytic forms of the parasite, nor will it prevent vivax or malariae infection when administered as a prophylactic. it is highly effective as a suppressive agent in patients with vivax or malariae malaria, in terminating acute attacks, and significantly lengthening the interval between treatment and relapse. in patients with falciparum malaria it abolishes the acute attack and effects complete cure of the infection, unless due to a resistant strain of p. falciparum . use of this drug is contraindicated in the presence of retinal or visual field changes either attributable to 4-aminoquinoline compounds or to a

United States - English - NLM (National Library of Medicine)

west-ward pharmaceutical corp - chloroquine phosphate (unii: 6e17k3343p) (chloroquine - unii:886u3h6uff) - chloroquine phosphate 250 mg - chloroquine phosphate tablets are indicated for suppressive treatment and for acute attacks of malaria due to p. vivax, p. malariae, p. ovale, and susceptible strains of p. falciparum. the drug is also indicated for the treatment of extraintestinal amebiasis. chloroquine phosphate tablets do not prevent relapses in patients with vivax or malariae malaria because it is not effective against exoerythrocytic forms of the parasite, nor will it prevent vivax or malariae infection when administered as a prophylactic. it is highly effective as a suppressive agent in patients with vivax or malariae malaria, in terminating acute attacks, and significantly lengthening the interval between treatment and relapse. in patients with falciparum malaria it abolishes the acute attack and effects complete cure of the infection, unless due to a resistant strain of p. falciparum. use of this drug is contraindicated in the presence of retinal or visual field changes either attributable to 4-aminoquinoline compounds or to any oth

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - chloroquine phosphate (unii: 6e17k3343p) (chloroquine - unii:886u3h6uff) - chloroquine phosphate 250 mg - chloroquine phosphate is indicated for the: - treatment of uncomplicated malaria due to susceptible strains of p. falciparum, p.malariae, p. ovale, and p.vivax . - prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. - treatment of extraintestinal amebiasis. chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. limitations of use in malaria: - do not use chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). - do not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, resistance to chloroquine phosphate tablets is widespread in p. falciparum , and is reported in p.vivax (see warnings). - concomitant therapy with an 8-aminoquinoline drug is necessary for treatment of the hypnozoite liver stage form

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - chloroquine phosphate (unii: 6e17k3343p) (chloroquine - unii:886u3h6uff) - chloroquine phosphate 500 mg - chloroquine phosphate tablets are indicated for suppressive treatment and for acute attacks of malaria due to p. vivax, p. malariae, p. ovale, and susceptible strains of p. falciparum. the drug is also indicated for the treatment of extraintestinal amebiasis. chloroquine phosphate tablets do not prevent relapses in patients with vivax or malariae malaria because it is not effective against exoerythrocytic forms of the parasite, nor will it prevent vivax or malariae infection when administered as a prophylactic. it is highly effective as a suppressive agent in patients with vivax or malariae malaria, in terminating acute attacks, and significantly lengthening the interval between treatment and relapse. in patients with falciparum malaria it abolishes the acute attack and effects complete cure of the infection, unless due to a resistant strain of p. falciparum. use of this drug is contraindicated in the presence of retinal or visual field changes either attributable to 4-aminoquinoline compounds or to any oth

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals of new york llc - chloroquine phosphate (unii: 6e17k3343p) (chloroquine - unii:886u3h6uff) - chloroquine phosphate tablets are indicated for the: - treatment of uncomplicated malaria due to susceptible strains of p. falciparum, p.malariae, p. ovale , and p.vivax. - prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. - treatment of extraintestinal amebiasis. chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. limitations of use in malaria: - do not use chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). - do not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, resistance to chloroquine phosphate tablets are widespread in p. falciparum, and is reported in p.vivax (see warnings ). - concomitant therapy with an 8-aminoquinoline drug is necessary for treatment of the hypnozoite liver s

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals of new york llc - chloroquine phosphate (unii: 6e17k3343p) (chloroquine - unii:886u3h6uff) - chloroquine phosphate tablets are indicated for the: - treatment of uncomplicated malaria due to susceptible strains of p. falciparum, p.malariae, p. ovale , and p.vivax. - prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. - treatment of extraintestinal amebiasis. chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. limitations of use in malaria: - do not use chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). - do not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, resistance to chloroquine phosphate tablets are widespread in p. falciparum, and is reported in p.vivax (see warnings ). - concomitant therapy with an 8-aminoquinoline drug is necessary for treatment of the hypnozoite liver stage forms of p.vivax and p.ovale (see dosage and administration ). use of chloroquine phosphate tablets for indications other than acute malaria is contraindicated in the presence of retinal or visual field changes of any etiology. use of chloroquine phosphate tablets are contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds.

United States - English - NLM (National Library of Medicine)

chartwell rx, llc - chloroquine phosphate (unii: 6e17k3343p) (chloroquine - unii:886u3h6uff) - chloroquine phosphate tablets are indicated for the: - treatment of uncomplicated malaria due to susceptible strains of p. falciparum, p. malariae, p. ovale, and p. vivax . - prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. - treatment of extraintestinal amebiasis. chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. limitations of use in malaria: - do not use chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). - do not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, resistance to chloroquine phosphate tablets is widespread in p. falciparum , and is reported in p. vivax (see warnings). - concomitant therapy with an 8-aminoquinoline drug is necessary for treat

United States - English - NLM (National Library of Medicine)

bayshore pharmaceuticals llc - chloroquine phosphate (unii: 6e17k3343p) (chloroquine - unii:886u3h6uff) - chloroquine phosphate tablets are indicated for the: - treatment of uncomplicated malaria due to susceptible strains of p. falciparum, p.malariae, p. ovale , and p.vivax. - prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. - treatment of extraintestinal amebiasis. chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. limitations of use in malaria: - do not use chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). - do not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, resistance to chloroquine phosphate tablets is widespread in p. falciparum, and is reported in p.vivax (see warnings). - concomitant therapy with an 8-aminoquinoline drug is necessary for treatment of the hypnozoite liver stage forms of p.vivax and p.ovale (see dosage and administration). use of chloroquine phosphate tablets for indications other than acute malaria is contraindicated in the presence of retinal or visual field changes of any etiology. use of chloroquine phosphate tablets is contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds.